About BioNTech
BioNTech is a company based in Mainz (Germany) founded in 2008 by Christoph Huber and Ozlem Tureci. BioNTech has raised $805.99 million across 12 funding rounds from investors including Fidelity Investments, Mirae Asset and Sanofi. The company has 6,770 employees as of December 31, 2024. BioNTech has completed 5 acquisitions, including Biotheus, CureVac and InstaDeep. BioNTech offers products and services including COMIRNATY and mRNA Cancer Immunotherapies. BioNTech operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.
- Headquarter Mainz, Germany
- Employees 6770 as on 31 Dec, 2024
- Founders Christoph Huber, Ozlem Tureci
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biontech Se Sponsored Adr
-
Annual Revenue
$2.98 B (USD)-27.92as on Dec 31, 2024
-
Net Profit
-$719.65 M (USD)-171.55as on Dec 31, 2024
-
EBITDA
-$373.62 M (USD)-131.73as on Dec 31, 2024
-
Total Equity Funding
$805.99 M (USD)
in 12 rounds
-
Latest Funding Round
$150 M (USD), Post-IPO
Apr 14, 2022
-
Investors
Fidelity Investments
& 18 more
-
Employee Count
6770
as on Dec 31, 2024
-
Investments & Acquisitions
Biotheus
& 4 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BioNTech
BioNTech is a publicly listed company on the NASDAQ with ticker symbol BNTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BioNTech
BioNTech offers a comprehensive portfolio of products and services, including COMIRNATY and mRNA Cancer Immunotherapies.
mRNA vaccine for preventing COVID-19 infections
Immunotherapies targeting cancer cells via mRNA technology
People of BioNTech
Unlock access to complete
Unlock access to complete
Leadership Team
124 people
Software Development Team
124 people
Operations Team
29 people
Legal and Compliance
28 people
Product Management Team
28 people
Human Resources and Administration
23 people
Data Analysis and Operations Team
14 people
Sales and Marketing
12 people
Unlock access to complete
Funding Insights of BioNTech
BioNTech has successfully raised a total of $805.99M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BioNTech
BioNTech has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Mirae Asset and Sanofi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
An investment platform is provided for diverse sectors and geographies.
|
Locked | Locked | Locked | |
|
Jebsen Capital is engaged in multi-strategy investments for Jebsen Group.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for BioNTech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioNTech
BioNTech has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Biotheus, CureVac and InstaDeep.
Investment portfolio details for BioNTech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of antibody-based therapeutics for cancer treatment
|
Locked | Locked | 2018 | Locked | |
|
Alternatives to antibiotics are developed via phage therapy expertise.
|
Locked | Locked | 2016 | Locked | |
|
AI and cloud-based automation solutions are provided for organizational optimization.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for BioNTech
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - BioNTech
Detailed financials for BioNTech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biontech Comparisons
Peer comparison for BioNTech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioNTech
BioNTech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
Detailed competitors of BioNTech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biontech
Complete news archive for BioNTech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioNTech
BioNTech was founded in 2008.
BioNTech is headquartered in Mainz, Germany. It is registered at Mainz, Rhineland-palatinate, Germany.
BioNTech is a funded company, having raised a total of $805.99M across 12 funding rounds to date.
As of Dec 31, 2024, the latest employee count at BioNTech is 6,770.
Annual revenue of BioNTech is $2.98B as on Dec 31, 2024.
BioNTech was established in 2008 in Mainz, Germany, within the biotechnology sector. Immunotherapeutics targeting cancer and additional diseases are developed, with an oncology pipeline encompassing mRNA-based treatments, modified cell therapies, antibodies, and small molecule immunomodulators. Optimization for specific action mechanisms, precise targeting, potency, and efficacy is emphasized in these efforts. Operations center on advancing therapeutic innovations for clinical applications.
BioNTech's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
BioNTech offers COMIRNATY and mRNA Cancer Immunotherapies.
Yes, BioNTech is publicly traded on NASDAQ under the ticker symbol BNTX.
BioNTech has 19 investors. Key investors include Fidelity Investments, Mirae Asset, Sanofi, Fosun Pharmaceutical, and Gates Foundation.
The ticker symbol of BioNTech is BNTX on NASDAQ.